Middle East Pharmaceutical Industries Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Mohammed Maher Al-Ghannam
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.3yrs |
| CEO ownership | n/a |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.7yrs |
Recent management updates
Recent updates
CEO
Mohammed Maher Al-Ghannam (43 yo)
6.3yrs
Tenure
Mr. Mohammed Maher MohammedLotfi Al-Ghannam is MD & Director of Middle East Pharmaceutical Industries Company from April 10, 2022 and its CEO from September 5, 2018. He was Director of Operations at the Mi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 6.3yrs | no data | no data | |
| Chief Financial Officer | 5.8yrs | no data | no data | |
| Chief Operating Officer | 1.5yrs | no data | no data | |
| Director of the Scientific Office Department | 6.9yrs | no data | no data | |
| Executive Director of Administrative Affairs | 5.9yrs | no data | no data | |
| Marketing Director | 2.3yrs | no data | no data | |
| Vice President of Sales | 2.3yrs | no data | no data | |
| Director of Human Resources | 1.5yrs | no data | no data | |
| Secretary of the Board of Directors | 1.3yrs | no data | no data |
2.3yrs
Average Tenure
43yo
Average Age
Experienced Management: 4016's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 2.7yrs | no data | no data | |
| Independent Non-Executive Director | 1.8yrs | no data | no data | |
| Independent Deputy Chairman | 1.3yrs | no data | no data | |
| Chairman | 2.7yrs | no data | no data | |
| Independent Non-Executive Director | 2.7yrs | no data | no data |
2.7yrs
Average Tenure
52yo
Average Age
Experienced Board: 4016's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 14:52 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Middle East Pharmaceutical Industries Company is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Appissa | Al Rajhi Capital |
| null null | SNB Capital |